Selected Publications

Academic Article

Year Title Altmetric
2022 The Heparanase/Syndecan-1 Axis in Cancer ProgressionThe FASEB Journal.  36. 2022
2022 Heparanase Blockade as a Novel Dual-Targeting Therapy for COVID-19Journal of Virology.  96. 2022
2022 Induction of heparanase 2 (Hpa2) expression by stress is mediated by ATF3 2022
2020 Heparanase-enhanced Shedding of Syndecan-1 and Its Role in Driving Disease Pathogenesis and Progression 2020
2020 Therapy-induced chemoexosomes: Sinister small extracellular vesicles that support tumor survival and progressionCancer Letters.  493:113-119. 2020
2020 Significance of host heparanase in promoting tumor growth and metastasis 2020
2020 Nuclear Heparanase Regulates Chromatin Remodeling, Gene Expression and PTEN Tumor Suppressor FunctionCells.  9. 2020
2020 Heparanase promotes myeloma stemness and in vivo tumorigenesis 2020
2020 Forty Years of Basic and Translational Heparanase ResearchAdvances in Experimental Medicine and Biology.  1221:3-59. 2020
2020 Heparanase and chemotherapy synergize to drive macrophage activation and enhance tumor growthCancer Research.  80:57-68. 2020
2020 Heparanase: A Dynamic Promoter of Myeloma ProgressionAdvances in Experimental Medicine and Biology.  1221:331-349. 2020
2019 Fibronectin on the surface of extracellular vesicles mediates fibroblast invasionAmerican Journal of Respiratory Cell and Molecular Biology.  60:279-288. 2019
2019 Proteases and glycosidases on the surface of exosomes: Newly discovered mechanisms for extracellular remodeling 2019
2018 Phase I study of the heparanase inhibitor roneparstat: An innovative approach for multiple myeloma therapy 2018
2018 Proteoglycan chemical diversity drives multifunctional cell regulation and therapeuticsChemical Reviews.  118:9152-9232. 2018
2018 Chemotherapy induces secretion of exosomes loaded with heparanase that degrades extracellular matrix and impacts tumor and host cell behavior 2018
2018 Opposing Functions of Heparanase-1 and Heparanase-2 in Cancer ProgressionTrends in Biochemical Sciences.  43:18-31. 2018
2017 Mesenchymal stem cells expressing osteoprotegerin variants inhibit osteolysis in a murine model of multiple myelomaBlood Advances.  1:2375-2385. 2017
2017 NEK2 induces osteoclast differentiation and bone destruction via heparanase in multiple myelomaLeukemia.  31:1648-1650. 2017
2017 Heparanase regulation of cancer, autophagy and inflammation: new mechanisms and targets for therapy 2017
2016 Heparanase: From basic research to therapeutic applications in cancer and inflammationDrug Resistance Updates.  29:54-75. 2016
2016 Chemotherapy induces expression and release of heparanase leading to changes associated with an aggressive tumor phenotype 2016
2016 Syndecan-1 (CD138) suppresses apoptosis in multiple myeloma by activating IGF1 receptor: Prevention by synstatinIGF1R inhibits tumor growthCancer Research.  76:4981-4993. 2016
2016 Heparanase-induced shedding of syndecan-1/CD138 in myeloma and endothelial cells activates VEGFR2 and an invasive phenotype: prevention by novel synstatins.Oncogenesis.  5:e202. 2016
2016 Fibronectin on the surface of myeloma cell-derived exosomes mediates exosome-cell interactionsJournal of Biological Chemistry.  291:1652-1663. 2016
2016 Family history of hematologic malignancies and risk of multiple myeloma: differences by race and clinical featuresCancer Causes and Control.  27:81-91. 2016
2016 Recent insights into cell surface heparan sulphate proteoglycans and cancer [version 1; referees: 3 approved]F1000Research.  5. 2016
2016 Targeting heparanase overcomes chemoresistance and diminishes relapse in myelomaOncotarget.  7:1598-1607. 2016
2015 Shed syndecan-1 translocates to the nucleus of cells delivering growth factors and inhibiting histone acetylation: A novel mechanism of tumor-host cross-talkJournal of Biological Chemistry.  290:941-949. 2015
2015 Heparanase is a host enzyme required for herpes simplex virus-1 release from cellsNature Communications.  6. 2015
2015 Insights into the key roles of proteoglycans in breast cancer biology and translational medicine. 2015
2014 Chemotherapy stimulates syndecan-1 shedding: A potentially negative effect of treatment that may promote tumor relapse 2014
2014 Heparan sulfate in the nucleus and its control of cellular functions 2014
2013 Heparanase inhibits osteoblastogenesis and shifts bone marrow progenitor cell fate in myeloma bone diseaseBONE.  57:10-17. 2013
2013 Heparanase: Multiple functions in inflammation, diabetes and atherosclerosis 2013
2013 Involvement of heparanase in atherosclerosis and other vessel wall pathologies 2013
2013 The heparanase/syndecan-1 axis in cancer: Mechanisms and therapies 2013
2013 Heparanase regulates secretion, composition, and function of tumor cell-derived exosomesJournal of Biological Chemistry.  288:10093-10099. 2013
2012 Heparanase enhances the insulin receptor signaling pathway to activate extracellular signal-regulated kinase in multiple myelomaJournal of Biological Chemistry.  287:41288-41296. 2012
2012 Targeting heparanase for cancer therapy at the tumor-matrix interface 2012
2012 Heparan sulfate chains of syndecan-1 regulate ectodomain sheddingJournal of Biological Chemistry.  287:9952-9961. 2012
2011 Heparanase-mediated loss of nuclear syndecan-1 enhances Histone Acetyltransferase (HAT) activity to promote expression of genes that drive an aggressive tumor phenotypeJournal of Biological Chemistry.  286:30377-30383. 2011
2011 Proteoglycans in cancer biology, tumour microenvironment and angiogenesisJournal of Cellular and Molecular Medicine.  15:1013-1031. 2011
2011 SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axisClinical Cancer Research.  17:1382-1393. 2011
2011 Heparanase plays a dual role in driving hepatocyte growth factor (HGF) signaling by enhancing HGF expression and activityJournal of Biological Chemistry.  286:6490-6499. 2011
2010 Heparanase enhances local and systemic osteolysis in multiple myeloma by upregulating the expression and secretion of RANKLCancer Research.  70:8329-8338. 2010
2010 Tumor-derived syndecan-1 mediates distal cross-talk with bone that enhances osteoclastogenesisJournal of Bone and Mineral Research.  25:1295-1304. 2010
2010 Heparanase-enhanced shedding of syndecan-1 by myeloma cells promotes endothelial invasion and angiogenesisBlood.  115:2449-2457. 2010
2010 Proteoglycans in health and disease: New concepts for heparanase function in tumor progression and metastasis 2010
2009 Myeloma bone diseaseJournal of Bone and Mineral Research.  24:1783-1788. 2009
2009 Heparanase: busy at the cell surfaceTrends in Biochemical Sciences.  34:511-519. 2009
2009 Syndecan-1 is required for robust growth, vascularization, and metastasis of myeloma tumors in vivoJournal of Biological Chemistry.  284:26085-26095. 2009
2009 Heparanase regulates levels of syndecan-1 in the nucleusPLoS ONE.  4. 2009
2008 Non-anticoagulant heparins and inhibition of cancer 2008
2008 Heparanase stimulation of protease expression implicates it as a master regulator of the aggressive tumor phenotype in myelomaJournal of Biological Chemistry.  283:32628-32636. 2008
2008 Non-enzymatic glycation of type I collagen diminishes collagen-proteoglycan binding and weakens cell adhesionJournal of Cellular Biochemistry.  104:1684-1698. 2008
2008 Syndecan-1: A dynamic regulator of the myeloma microenvironmentClinical and Experimental Metastasis.  25:149-159. 2008
2007 The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapyBlood.  110:2041-2048. 2007
2007 Heparanase enhances syndecan-1 shedding: A novel mechanism for stimulation of tumor growth and metastasisJournal of Biological Chemistry.  282:13326-13333. 2007
2006 Expression of CD138 (syndecan-1) in renal cell carcinoma is reduced with increasing nuclear gradeApplied Immunohistochemistry and Molecular Morphology.  14:173-177. 2006
2005 HSulf-1 and HSulf-2 are potent inhibitors of myeloma tumor growth in vivoJournal of Biological Chemistry.  280:40066-40073. 2005
2005 Enzymatic remodeling of heparan sulfate proteoglycans within the tumor microenvironment: Growth regulation and the prospect of new cancer therapiesJournal of Cellular Biochemistry.  96:897-905. 2005
2005 Expression of heparanase by primary breast tumors promotes bone resorption in the absence of detectable bone metastasesCancer Research.  65:5778-5784. 2005
2005 Identification of an invasion regulatory domain within the core protein of syndecan-1Journal of Biological Chemistry.  280:3467-3473. 2005
2005 Heparanase promotes the spontaneous metastasis of myeloma cells to boneBlood.  105:1303-1309. 2005
2005 Dynamic remodeling of syndecan-1 structure regulates myeloma tumor growth and metastasis in vivo 2005
2004 Heparan sulfate proteoglycans and heparanase - Partners in osteolytic tumor growth and metastasis 2004
2004 Heparanase degrades syndecan-1 and perlecan heparan sulfate: Functional implications for tumor cell invasionJournal of Biological Chemistry.  279:8047-8055. 2004
2003 High Heparanase Activity in Multiple Myeloma Is Associated with Elevated Microvessel DensityCancer Research.  63:8749-8756. 2003
2003 The epidermal growth factor-like domains of the human EMR2 receptor mediate cell attachment through chondroitin sulfate glycosaminoglycansBlood.  102:2916-2924. 2003
2003 Heparan sulfate regulates targeting of syndecan-1 to a functional domain on the cell surfaceJournal of Biological Chemistry.  278:12888-12893. 2003
2003 Expression of syndecan-1 is a sensitive marker for cutaneous plasmacytomaJournal of Cutaneous Pathology.  30:18-22. 2003
2003 Vitronectin's basic domain is a syndecan ligand which functions in trans to regulate vitronectin turnover 2003
2002 Syndecan-1 in B lymphoid malignanciesAnnals of Hematology.  81:125-135. 2002
2002 Syndecan-1 is strongly expressed in the anagen hair follicle outer root sheath and in the dermal papilla but expression diminishes with involution of the hair follicleAmerican Journal of Dermatopathology.  24:484-489. 2002
2002 Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cellsBlood.  100:3002-3007. 2002
2002 Soluble syndecan-1 promotes growth of myeloma tumors in vivoBlood.  100:610-617. 2002
2002 Neoglycans, carbodiimide-modified glycosaminoglycans: A new class of anticancer agents that inhibit cancer cell proliferation and induce apoptosisCancer Research.  62:3722-3728. 2002
2002 Sperm protein 17 is not expressed on normal leukocytes [3] (multiple letters)Blood.  99:3479-3481. 2002
2002 Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cellsBlood.  99:1745-1757. 2002
2002 6xHis promotes binding of a recombinant protein to heparan sulfate 2002
2002 Measurements of glycosaminoglycan-based cell interactionsMethods in Cell Biology.  2002:297-308. 2002
2002 The level of syndecan-1 expression is a distinguishing feature in behavior between keratoacanthoma and invasive cutaneous squamous cell carcinomaModern Pathology.  15:45-49. 2002
2001 Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: Shed syndecan-1 accumulates in fibrotic regionsModern Pathology.  14:1052-1058. 2001
2001 Sperm protein 17 is expressed on normal and malignant lymphocytes and promotes heparan sulfate-mediated cell-cell adhesionBlood.  98:2160-2165. 2001
2001 Acantholysis and spongiosis are associated with loss of syndecan-1 expressionJournal of Cutaneous Pathology.  28:135-139. 2001
2001 Heparan sulfate proteoglycans in invasion and metastasisSeminars in Cell and Developmental Biology.  12:89-98. 2001
2001 Regulatory roles of syndecans in cell adhesion and invasion.Methods in Molecular Biology.  171:495-503. 2001
2000 High levels of soluble syndecan-1 in myeloma-derived bone marrow: Modulation of hepatocyte growth factor activityBlood.  96:3139-3146. 2000
2000 Syndecan-1 is targeted to the uropods of polarized myeloma cells where it promotes adhesion and sequesters heparin-binding proteinsBlood.  96:2528-2536. 2000
2000 The cysteine-rich domain of human ADAM 12 supports cell adhesion through syndecans and triggers signaling events that lead to β1 integrin-dependent cell spreading 2000
2000 Syndecan-1 expression is decreased with increasing aggressiveness of basal cell carcinomaAmerican Journal of Dermatopathology.  22:119-122. 2000
2000 Matrix metalloproteinases in multiple myeloma 2000
1999 Syndecan-1 expression is diminished in acantholytic cutaneous squamous cell carcinomaJournal of Cutaneous Pathology.  26:386-390. 1999
1999 Syndecan-1 expression suppresses the level of myeloma matrix metalloproteinase-9British Journal of Haematology.  104:365-373. 1999
1999 Syndecan-1 (CD 138) in myeloma and lymphoid malignancies: A multifunctional regulator of cell behavior within the tumor microenvironment 1999
1999 Syndecan-1 expression is induced in the stroma of infiltrating breast carcinomaAmerican Journal of Clinical Pathology.  112:377-383. 1999
1998 Multiple heparan sulfate chains are required for optimal syndecan-1 functionJournal of Biological Chemistry.  273:29965-29971. 1998
1998 Heparan sulfate proteoglycans as adhesive and anti-invasive molecules: Syndecans and glypican have distinct functionsJournal of Biological Chemistry.  273:22825-22832. 1998
1998 Syndecan-1 is a multifunctional regulator of myeloma pathobiology: Control of tumor cell survival, growth, and bone cell differentiationBlood.  91:2679-2688. 1998
1997 Elevated levels of shed syndecan-1 correlate with tumour mass and decreased matrix metalloproteinase-9 activity in the serum of patients with multiple myelomaBritish Journal of Haematology.  99:368-371. 1997
1996 Heparan sulfate proteoglycans mediate aggregation of human B lymphoid cellsThe FASEB Journal.  10. 1996
1996 Photoaffmity analogs for the study of glycosaminoglycan biosynthetic enzymes in human myeloma cell linesThe FASEB Journal.  10. 1996
1995 Heparan sulfate-mediated cell aggregation: Syndecans-1 and -4 mediate intercellular adhesion following their transfection into human B lymphoid cellsJournal of Biological Chemistry.  270:5077-5083. 1995
1995 Syndecans as Anti-invasive Molecules on the Surface of Tumor Cells 1995
1994 Expression of syndecan-1 inhibits cell invasion into type I collagenJournal of Biological Chemistry.  269:20013-20019. 1994
1994 Interactions of syndecan-1 and heparin with human collagensGlycobiology.  4:327-332. 1994
1994 Fine structure of heparan sulfate regulates syndecan-1 function and cell behaviorJournal of Biological Chemistry.  269:13100-13106. 1994
1994 Interleukin-6 regulates expression of the syndecan-1 proteoglycan on b lymphoid cellsCellular Immunology.  153:456-467. 1994
1993 Expression of syndecan regulates human myeloma plasma cell adhesion to type I collagenBlood.  81:767-774. 1993
1992 Adhesion of B lymphoid (MPC-11) cells to type I collagen is mediated by the integral membrane proteoglycan, syndecanJournal of Immunology.  148:3902-3911. 1992
1992 Functional and molecular characterization of single, (4‐hydroxy‐3‐nitrophenyl)acetyl (NP)‐specific, IgG1+ B cells from antibody‐secreting and memory B cell pathways in the C57BL/6 immune response to NPEuropean Journal of Immunology.  22:3001-3011. 1992
1992 Syndecan-1, a cell-surface proteoglycan, changes in size and abundance when keratinocytes stratifyJournal of Investigative Dermatology.  99:390-396. 1992
1991 Expression of syndecan, a putative low affinity fibroblast growth factor receptor, in the early mouse embryo 1991
1991 Epithelial-mesenchymal interactions in uterus and vagina alter the expression of the cell surface proteoglycan, syndecanDevelopmental Biology.  148:63-74. 1991
1990 Syndecan, a developmentally regulated cell surface proteoglycan that binds extracellular matrix and growth factors. 1990
1989 B lymphocytes express and lose syndecan at specific stages of differentiation. 1989
1988 Molecular polymorphism of a cell surface proteoglycan: Distinct structures on simple and stratified epithelia 1988
1986 Fibroblasts promote the formation of a continuous basal lamina during myogenesis in vitro 1986
1985 The Extracellular Matrix of Skeletal Muscle 1985
1984 Changes in the synthesis of minor cartilage collagens after growth of chick chondrocytes in 5-bromo-2′-deoxyuridine or to senescenceExperimental Cell Research.  151:171-182. 1984
1984 Monoclonal antibodies against chicken type IV and V collagens: Electron microscopic mapping of the epitopes after rotary shadowing 1984
1983 The use of monoclonal antibodies to fragments of chicken type IV collagen in structural and localization studiesJournal of Biological Chemistry.  258:5794-5797. 1983
1983 Monoclonal antibodies against chicken type V collagen: Production, specificity, and use for immunocytochemical localization in embryonic cornea and other organs 1983
1982 Domain and basement membrane specificity of a monoclonal antibody against chicken type IV collagen 1982
1982 Domain and basement membrane specificity of a monoclonal antibody against chicken type IV collagen. 1982


Year Title Altmetric
2012 Heparanase, a multifaceted protein involved in cancer, chronic inflammation, and kidney dysfunction.  824-854. 2012
2012 Targeting syndecan shedding in cancer.  802-812. 2012
2010 Proteoglycans and cancer.  191-215. 2010

Research Overview

  • The tumor microenvironment has emerged as a major regulator of tumor growth and progression. The long-term goal of the Sanderson lab is to determine how tumor-host cell interactions mediated by heparan sulfate and the enzyme heparanase regulate the tumor microenvironment and to use that knowledge to design new cancer therapies. We have shown that heparan sulfate proteoglycans and heparanase promote tumor growth and metastasis of multiple myeloma and breast tumors, two tumors that home to and grow within bone. Our hypothesis is that heparan sulfate drives tumor growth by concentrating heparin-binding growth factors (e.g., FGF-2, VEGF, HGF) within the tumor microenvironment and promoting interactions of these growth factors with their high affinity receptors. Thus, interfering with heparan sulfate function has the potential to attenuate numerous signaling pathways important in tumor growth and metastasis. Our current experimental focus is two-fold. First, we are examining how enzymes that modify heparan sulfate such as heparanase alter tumor behavior and promotes an aggressive tumor phenotype. We have recently discovered that this occurs, at least in part, via heparanase regulation of tumor secreted exosomes. These small vesicles contain proteins and nucleic acids that can be transferred horizontally to other cells within the tumor microenvironment and beyond and thus act as important mediators of intercellular communication. Second, we are developing novel heparanase inhibitors and testing them as potential anti-cancer drugs. This work will lead to a better understanding of the tumor microenvironment and how it can be disrupted to block tumor growth. Our work is currently funded by the National Institutes of Health.
  • Principal Investigator On

  • Heparan Sulfate and Cancer Growth Control  awarded by UNIVERSITY OF ALABAMA HEALTH SERVICES FOUNDATION
  • Heparanase In Tumor Progression, Metastasis and Chemoresistance  awarded by National Cancer Institute/NIH/DHHS
  • Heparanase Inhibitor as Anti-Metastatic Therapy for Myeloma.  awarded by Multiple Myeloma Research Foundation
  • Heparanase Regulation of Myeloma Metastasis: Mechanism and Therapy  awarded by National Cancer Institute/NIH/DHHS
  • Heparanase Regulation of Myeloma Metastasis: Mechanism and Therapy  awarded by National Cancer Institute/NIH/DHHS
  • Heparanase Regulation of Tumor Host Interactions in Myeloma and Breast Cancer  awarded by National Cancer Institute/NIH/DHHS
  • Heparanase Regulation of Tumor Progression Via Exosomes and Autophagosomes  awarded by United States - Israel Binational Science Foundation
  • Heparanase and Renal Damage in Myeloma  awarded by Conquer Cancer Foundation of ASCO
  • Nanosight NS300 for Nanoparticle Tracking  awarded by UNIVERSITY OF ALABAMA HEALTH SERVICES FOUNDATION
  • Novel Heparanase Inhibitors for Cancer Therapy  awarded by National Cancer Institute/NIH/DHHS
  • Novel Heparanase Inhibitors for Myeloma Treatment: Basic Aspects and Clinical Significance  awarded by United States - Israel Binational Science Foundation
  • Novel Role for Shed Syndecan 1 in Promoting an Aggressive Tumor Phenotype  awarded by National Cancer Institute/NIH/DHHS
  • Optimizing Small Molecule Inhibitors of Heparanase for Myeloma Therapy  awarded by Leukemia and Lymphoma Society
  • Private Grant  awarded by SIGMA-TAU RESEARCH, INC.
  • Private Grant  awarded by SIGMA-TAU RESEARCH, INC.
  • Private Grant  awarded by SIGMA-TAU RESEARCH, INC.
  • Synstatin Therapy for Multiple Myeloma  awarded by University of Wisconsin-Madison
  • Investigator On

  • A Novel Exosomal Inflammatory Pathway  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS
  • A Pathogenic Smoke Associated Neutrophilic Exosomal Pathway  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS
  • Active - Major Program Leader - Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS
  • Comprehensive Cancer Center Core Support Grant - Cancer Cell Biology Program  awarded by National Cancer Institute/NIH/DHHS
  • Comprehensive Cancer Center Core Support Grant - Cancer Cell Biology Program  awarded by National Cancer Institute/NIH/DHHS
  • Endothelial Glycocalyx Disintegrity: Repairing the Damage Caused by Trauma-Hemorrhage  awarded by National Institute of General Medical Sciences/NIH/DHHS
  • Epigenetic contribution to the excess risk of MGUS in African Americans  awarded by National Cancer Institute/NIH/DHHS
  • Gene-Engineered and Targeted Stem Cell Therapy for Myeloma  awarded by National Cancer Institute/NIH/DHHS
  • HL-A New Pathway for Neutrophil-Induced Airway Inflammation  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS
  • Lumina III System for UAB Optical Imaging  awarded by NIH - OFFICE OF THE DIRECTOR
  • Mechanisms Driving Endothelial Angiopoietin-2 Expression and Vascular Dysfunction during Pediatric Sepsis  awarded by National Institute of General Medical Sciences/NIH/DHHS
  • Molecular Characterization of Myeloma and Related Asymptomatic Precursor States  awarded by National Cancer Institute/NIH/DHHS
  • Role of Fumarate Hydratase in Renal Hypoxia and Tumorigenesis  awarded by National Cancer Institute/NIH/DHHS
  • The Role of Exosome Heparanase and miRNAs as Biomarkers for Myeloma  awarded by National Cancer Institute/NIH/DHHS
  • The Thrombospondin1-TGF-Beta Axis in Multiple Myeloma  awarded by National Cancer Institute/NIH/DHHS
  • Education And Training

  • Stanford University Pediatrics, Postdoctoral Research
  • Doctor of Philosophy in Cell / Cellular Biology and Anatomical Sciences, University of Alabama at Birmingham 1986
  • Full Name

  • Ralph Sanderson